PH21328A - Pharmaceutical agent for the treatment of diabetes mellitus - Google Patents

Pharmaceutical agent for the treatment of diabetes mellitus

Info

Publication number
PH21328A
PH21328A PH31011A PH31011A PH21328A PH 21328 A PH21328 A PH 21328A PH 31011 A PH31011 A PH 31011A PH 31011 A PH31011 A PH 31011A PH 21328 A PH21328 A PH 21328A
Authority
PH
Philippines
Prior art keywords
treatment
diabetes mellitus
denotes
pharmaceutical agent
phe
Prior art date
Application number
PH31011A
Other languages
English (en)
Inventor
Grau Ulrich
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PH21328A publication Critical patent/PH21328A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • C07K14/625Extraction from natural sources
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/26Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH31011A 1983-07-22 1984-07-20 Pharmaceutical agent for the treatment of diabetes mellitus PH21328A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833326473 DE3326473A1 (de) 1983-07-22 1983-07-22 Pharmazeutisches mittel zur behandlung des diabetes mellitus

Publications (1)

Publication Number Publication Date
PH21328A true PH21328A (en) 1987-10-13

Family

ID=6204661

Family Applications (1)

Application Number Title Priority Date Filing Date
PH31011A PH21328A (en) 1983-07-22 1984-07-20 Pharmaceutical agent for the treatment of diabetes mellitus

Country Status (19)

Country Link
US (1) US4608364A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0132769B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6042334A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE31625T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU564648B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1236012A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3326473A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK172456B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8504456A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI79786C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR81550B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT34889A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE57690B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL72468A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO167187C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ208960A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH21328A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT78941A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA845621B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
ES2053723T3 (es) * 1987-02-25 1994-08-01 Novo Nordisk As Nuevos derivados de insulina.
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
US6875589B1 (en) 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
ES2061797T3 (es) * 1988-06-23 1994-12-16 Hoechst Ag Mini-proinsulina, su preparacion y empleo.
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE3936876A1 (de) * 1989-11-06 1991-05-23 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
WO1992010284A2 (en) 1990-12-07 1992-06-25 Cnc Development, Inc. Catalytic chemical reactor
YU66892A (sh) * 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin
TW224471B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1991-11-26 1994-06-01 Lilly Co Eli
EP0545198B1 (de) * 1991-11-29 1999-09-15 Hoechst Aktiengesellschaft Peptide mit insulinartiger Wirkung
CA2087087C (en) * 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
DE19649350A1 (de) * 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
WO1999021578A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
PT1165119E (pt) * 1999-04-08 2004-02-27 Genentech Inc Composicao baseada em polipeptidos com cargas opostas
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
MX2011003117A (es) 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
NZ592283A (en) 2008-10-17 2012-09-28 Sanofi Aventis Deutschland Combination of an insulin and the GLP-1 agonist AVE0010
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
DK2498801T3 (en) 2009-11-13 2018-05-07 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN
CN107308442B (zh) 2009-11-13 2022-10-18 赛诺菲-安万特德国有限公司 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 2型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
US10689430B2 (en) * 2016-05-25 2020-06-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
WO2025068976A1 (en) 2023-09-28 2025-04-03 Biotts Inc. Compositions comprising insulin agonists, and said compositions for use in the treatment of diabetes or obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
IL66610A (en) * 1981-08-27 1985-11-29 Lilly Co Eli Human proinsulin pharmaceutical formulations
IL66611A0 (en) * 1981-08-27 1982-12-31 Lilly Co Eli Pharmaceutical formulations comprising human insulin and human c-peptide
ZW17682A1 (en) * 1981-08-27 1982-11-24 Lilly Co Eli Pharmaceutical formulations comprising human insulin human c-peptide and human proinsulin
NL8201650A (nl) * 1982-04-21 1983-11-16 Akzo Nv Semisynthetische bereiding van humane insuline.

Also Published As

Publication number Publication date
NO842978L (no) 1985-01-23
FI79786C (fi) 1990-03-12
ES534488A0 (es) 1985-05-01
FI842915A0 (fi) 1984-07-19
NO167187B (no) 1991-07-08
FI842915L (fi) 1985-01-23
IE57690B1 (en) 1993-03-10
CA1236012A (en) 1988-05-03
DE3326473A1 (de) 1985-01-31
JPH0469128B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-11-05
US4608364A (en) 1986-08-26
ES8504456A1 (es) 1985-05-01
AU564648B2 (en) 1987-08-20
GR81550B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-12-11
DK358384D0 (da) 1984-07-20
DE3468323D1 (en) 1988-02-11
IL72468A (en) 1989-08-15
ATE31625T1 (de) 1988-01-15
PT78941A (de) 1984-08-01
ZA845621B (en) 1985-02-27
NZ208960A (en) 1989-02-24
IL72468A0 (en) 1984-11-30
DK172456B1 (da) 1998-08-24
DK358384A (da) 1985-01-23
EP0132769A1 (de) 1985-02-13
AU3091784A (en) 1985-01-24
EP0132769B1 (de) 1988-01-07
NO167187C (no) 1991-10-16
IE841890L (en) 1985-01-22
HUT34889A (en) 1985-05-28
JPS6042334A (ja) 1985-03-06
FI79786B (fi) 1989-11-30

Similar Documents

Publication Publication Date Title
DE3468323D1 (en) Pharmaceutical formulation for the treatment of diabetes mellitus
ES8504678A1 (es) Procedimiento para la preparacion de un derivado de insulina
DE68929217D1 (en) Insulinotropes hormon
NZ230280A (en) Pharmaceutical formulation containing an insulin derivative modified with a base, with an isoelectric point between 5.8 - 8.5, and with a zinc ion content of from 2mug - 200mug of zinc/iu
DE69025336D1 (de) Antihypertensive Zubereitungen und deren Verwendung
EP0552256A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
HUT38950A (en) Process for producing 2-substituted-1,3-propylidene-diphosphonate derivatives and pharmaceutical compositions containing them as active agents
ZA894508B (en) Pharmaceutical compounds
EP0221728A3 (en) Monosaccharide containing wound healing preparation
NZ216048A (en) Quinolylglycinamide derivatives, and pharmaceutical compositions containing such
JPS5344616A (en) Injections
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
GB2021581A (en) Stabilisation of PGl2 derivatives
IL111361A0 (en) Pharmaceutical compositions for the treatment of insulin dependent diabetes mellitus (iddm)
ZA902167B (en) Thienylpiperazines,process for the preparation thereof,the use thereof,and pharmaceuticals containing these and the preparation thereof
JPS5634629A (en) Anti-arteriosclerotic agent containing aminobenzoic acid derivative as effective component